A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 175 participants.
Also called NCT07839936
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 175 participants
- Sponsor
- Registry
-
NCT07839936 -
2026-525691-26-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07839936. Randomized; double masking; primary purpose treatment. Start 2026-09-24 (actual); primary completion 2028-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
- Acronym
- HEART-3
- Condition
- Atherosclerosis
- Condition
- Cardiovascular Disease
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- VERVE-102
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07839936- Content hash
1d2516313a4bbe58e4653997fb12cfafe116c40caa45bea8bccfa67b0fc11994